Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
BioPharma DiveBioPharma Dive staffOctober 30, 2026
Lilly s better-than-expected results allayed concerns for now over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.